

Association of multidrug-resistant bacteria and clinical outcomes in patients with infected diabetic foot in a Peruvian Hospital: A retrospective cohort analysis

Authors

Marlon Yovera-Aldana^{1*}, Paola Sifuentes-Hermenegildo^{2,3}, Martha Sofia Cervera-Ocaña⁴, Edward Mezones-Holguin^{5,6}

Filiations

¹ Grupo de Investigación de Neurociencias, Efectividad clínica y Salud Pública, Universidad Científica del Sur, Lima, Peru.

² Servicio de Endocrinología, Departamento de Medicina, Hospital María Auxiliadora, Lima, Peru.

³ Red de Eficacia Clínica y Sanitaria, Lima, Perú.

⁴ Facultad de Ciencias Médicas, Universidad César Vallejo. Trujillo, Peru.

⁵ Centro de Estudios Económicos y Sociales en Salud, Universidad San Ignacio de Loyola, Lima, Peru.

⁶ Soluciones de Epi-gnosis. Piura, Peru.

Corresponding author

E-mail: myovera@cientifica.edu.pe (MYA)

ABSTRACT

Objective: To evaluate the association of multidrug-resistant bacteria (MDRB) and adverse clinical outcomes in patients with infected diabetic foot (IDF) in a Peruvian hospital.

Materials and Methods: This retrospective cohort study evaluated patients treated in the Diabetic Foot Unit of a General Hospital in Lima, Peru. MDRB was based on resistance to more than two pharmacological groups across six clinically significant genera. The primary outcome was death due to complications of the IDF and/or major amputation. Other outcomes included minor amputation, hospitalization, and a hospital stay longer than 14 days. Relative risks were estimated using Poisson regression for all outcomes.

Results: The study included 192 IDF patients with a mean age of 59.9 years; 74% were males. A total of 80.8% exhibited MDRB. The primary outcome had an incidence rate of 23.2% and 5.4% in patients with and without MDRB, respectively ($p = 0.01$). After adjusting for sex, age, bone involvement, severe infection, ischemia, diabetes duration, and glycosylated hemoglobin, MDRB showed no association with the primary outcome (RR 3.29; 95% CI, 0.77 - 13.9), but did with hospitalization longer than 14 days (RR 1.43; 95% CI, 1.04 - 1.98).

Conclusions: Our study found no association between MDRB and increased mortality and/or major amputation but did find a correlation with prolonged hospitalization. The high proportion of MDRB could limit the demonstration of the relationship. It is urgent to apply continuous evaluation of bacterial resistance, implement a rational plan for antibiotic use, and maintain biosafety to confront this threat.

Keywords: Diabetic foot; Bacterial infections; Drug-resistant, Multiple, Bacterial; Amputation, surgical; Cohort studies; Peru

Introduction

Infected Diabetic Foot (IDF) is one of the leading causes of hospitalization in diabetic foot units, with 15-20% of cases requiring major amputation[1,2]. In Peru, it accounts for 18.9% of diabetes-related hospital admissions, and 61% of these cases develop sepsis[3]. Treatment costs are five times higher for patients who develop this complication, which impacts the healthcare system and patients' quality of life, particularly in developing countries[4]. Given the magnitude and significant impact of this complication, effective and personalized treatment is needed.

Antibiotic resistance poses a threat to the successful treatment of IDF[5]. The prevalence of Multidrug-Resistant Bacteria (MDRB) varies from 14% to 66%[6,7], depending on the country studied. MDRB is associated with protracted recovery, increased need for surgical procedures, prolonged hospital stays, and higher treatment costs[8]. Additionally, it results in increased protein-nutritional requirements, higher oxygen consumption, disturbed glycemic control, and reduced hemoglobin levels[9]. As these are polymicrobial infections, the use of broad-spectrum antibiotics is recommended for severe infections, subsequently deescalating according to the antibiogram[10]. For a proper IDF approach, it is mandatory to determine the bacteriological resistance profile at each healthcare facility and to devise a treatment algorithm based on those results[11].

The influence of MDRB on the clinical outcomes of IDF is not well understood[7], with scant research conducted in Latin America on the subject[3]. Factors such as inappropriate antibiotic selection due to the lack of an antibiogram, reduced antibiotic concentration in tissues caused by peripheral ischemia, and colonization by resistant strains due to frequent

hospitalizations or prolonged treatments have been documented[12]. Furthermore, at the local level, only 30% of outpatient individuals have an HbA1c level below 7%, and a mere 10% have comprehensive metabolic control (involving lipids, weight, blood pressure, and blood glucose). Consequently, an adverse clinical outcome can potentially be expected when faced with an MDRB infection[13]. This study aims to assess the relationship between MDRB and its outcomes in IDF patients at a public hospital in Peru.

Material and Methods

Study Design and Setting

We conducted a retrospective cohort study on patients with DFI. We used secondary data from patients who attended the Diabetic Foot Unit (DFU) at the Maria Auxiliadora Hospital in Lima, Peru, between January 2017 and December 2019. This hospital is located in southern Lima and provides medical care to 2.5 million economically disadvantaged people. The DFU of the Endocrinology service has been the first line of treatment for IDF patients since 2015. Based on the severity, the DFU decides whether hospitalization or outpatient management is necessary.

Patients

We included patients diagnosed with IDF as per the Infectious Diseases Society of America (IDSA) classification[10]. Additionally, those with a positive culture taken by the DFU staff within the first 48 hours of contact were included. Patients were excluded if they had extensive necrosis due to severe ischemia, no opportunity for culture, culture samples

obtained via swabs or aspiration, follow-up of less than a month if not hospitalized, infected peripheral venous insufficiency, and pressure ulcers.

Sample Size

After applying the inclusion and exclusion criteria, we obtained a sample size of 192 patients. The power of the sample was 88%, considering a proportion of 82% of the primary outcome in exposed subjects, 78% in non-exposed subjects, a confidence level of 95%, and a 4:1 ratio between exposed and non-exposed subjects.

Variables

Multidrug-Resistant Bacteria (MDRB)

MDRB was defined as a lack of susceptibility to at least one agent in three or more classes of antimicrobials for each bacterial genus: *Staphylococcus sp.*, *Enterococcus sp.*, *Enterobacteriaceae*, *Pseudomonas sp.*, and *Acinetobacter sp.* Innate resistances to some drugs were not considered for this definition. **S1- S5 Tables.** show the criteria to consider resistance for each bacterial genus[14].

Adverse Clinical Outcomes

The primary composite outcome consisted of death due to IDF complications and/or major amputation (above the ankle). Secondary outcomes were death related to the diabetic foot, major amputation, minor amputation (below the ankle), hospitalization solely for medical treatment, and prolonged stay (more than 14 days).

Diabetic Foot Characteristics

We described the characteristics of the lesion and the patient upon admission to the DFU using the San Elian scale. This tool includes 10 variables: description of depth, infection,

ischemia, neuropathy, location, topography, number of zones, edema, and degree of inflammation[15]. The largest and smallest diameters of the ulcer were recorded, and the area was calculated using the ellipse formula. The degree of infection was based on the IDSA consensus[10]. Peripheral arterial disease classification was obtained from arterial plethysmography reports, with positive results if biphasic, monophasic, or absence of wave patterns were present. Peripheral neuropathy was diagnosed if there was a loss of protective sensation evaluated with a monofilament. The glomerular filtration was calculated using the CKD-EPI formula[16]. Previous exposure to antibiotics in the last year, as well as previous amputation or hospitalization for diabetic foot, was documented. Furthermore, we recorded the levels of hemoglobin, albumin, leukocytes, and creatinine at the time of the acute episode. We accepted HbA1c values up to one month old (**S6 Table**).

Procedures

Authorization was obtained from the Endocrinology department head to access DFU data. The endocrinology service continuously records the outcomes of its patients for administrative purposes. This spreadsheet was provided without personally identifiable information. A first request was made in February 2019 and then in December 2019. Two authors completed other data of interest by reviewing the medical records from February 2019 to January 2020 if necessary. (**S7 Table**).

Management Guide

The endocrinology service staff applied diagnostic and therapeutic procedures following the International Working Group of Diabetic Foot Guide for the management of infection, peripheral arterial disease, and ulcers[17]. The team consisted of four doctors and two nurses trained in comprehensive management.

Microbiological Analysis

The DFU staff obtained culture samples via tissue biopsy following the wound debridement using the standard procedure[18]. The hospital laboratory staff conducted the bacterial identification analysis and antibiotic susceptibility tests using an automated system, VITEK® 2 (BioMérieux Laboratory, Argentina)[19].

Statistical Analysis

Clinical and laboratory characteristics were described quantitatively, using either mean with standard deviation or median with interquartile range, depending on the normality assessed by the Shapiro-Wilk test. Categorical variables were presented with absolute and relative frequencies. Moreover, the isolated bacteria were characterized by percentages, according to the Gram stain type and genus. To determine the differences between the groups with and without MDRB, we used the Student's T-test or U-Mann Whitney test for numerical variables based on distribution. For categorical variables, we employed the Pearson's Chi-square test or Fisher's exact test. We also assessed the incidence of the primary composite outcome based on demographic and clinical characteristics.

A multivariate analysis was performed using a generalized linear model with a Poisson function, logarithmic link, and robust variance to determine the relative risk (RR) for the primary and secondary outcomes. An unadjusted model and three adjusted models were developed based on epidemiological variables. Model 1 was adjusted for age and sex, Model 2 for bone involvement, severe infection, and peripheral arterial disease, and Model 3 for diabetes duration and HbA1C levels. The analysis was conducted using the STATA® software (version 15.1, Texas, USA), and a significance level of 5% was applied for all hypothesis tests.

Ethics

The Institutional Ethics Committee for Research at María Auxiliadora Hospital approved the development of this research project, under the code HA/CIEI/019/19. The data provided by the Endocrinology Service did not contain any personally identifiable information. If it was necessary to review medical records for missing data, the collection forms did not contain identifying data. Only the lead author had access to the data.

RESULTS

The initial database comprised 582 subjects evaluated by the UPD between 2017 and 2019. Based on eligibility criteria, we excluded 390 patients, with the primary reason for exclusion being the absence of a bacterial culture. Ultimately, 192 patients were included in the study (Fig 1).

Figure 1. Flowchart of patients included in the study.

Out of the total, 155 patients (80.8%) had a MDRB infection, 74% were males, with an average age of 59.9 ± 12.9 years. The median duration of diabetes mellitus was 12 years, the average HbA1c was 10%, and 81% of the patients had an HbA1c level of ≥ 7 . Notably, 28.1% of the patients developed a recurrent ulcer. As per the Wagner classification of DFI, 50.5% were classified as grade IV, and 88% had a moderate to severe infection according to the IDSA guidelines. The remaining demographic and clinical characteristics of the patients are shown in Table 1.

Table 1. Clinical and demographic characteristics according to the MDR organism.

191

Variable	MDRB (+) n(%)	MDRB (-) n(%)	Total n(%)	<i>p-value</i>
General	155 (80.8)	37 (19.3)	192 (100)	
Demographic				
Male	112 (72.3)	30 (81.1)	142 (74.0)	0.27
Age (years), mean $\pm$ SD	60.8 $\pm$ 12.9	56.5 $\pm$ 12.8	59.9 $\pm$ 12.9	0.07
Age > 60 years	83 (53.6)	13 (35.1)	96 (50.0)	0.04
DM duration (years), Med (IQR)	12 (9 to 20)	12 (8 to 17)	12 (8 to 20)	0.72
Diabetic foot ulcer				
Reulceration	44 (28.4)	10 (27.0)	54 (28.1)	0.87
Total ulcer area (cm ²), Med (IQR)	15 (6 to 32)	18 (6 to 24)	15 (6 to 30)	0.83
Wagner classification				
1	4 (2.6)	1 (2.7)	5 (2.6)	0.15
2	12 (7.7)	6 (16.2)	18 (9.4)	
3	55 (35.5)	17 (46.0)	72 (37.5)	
4	84 (54.2)	13 (35.1)	97 (50.5)	
IDSA infection grade				
Mild	15 (9.7)	8 (21.6)	23 (12.0)	0.08
Moderate	104 (67.1)	18 (48.6)	122 (63.5)	
Severe	36 (23.2)	11 (29.7)	47 (24.5)	
Peripheral arterial disease	62 (40.0)	9 (24.3)	71 (37.0)	0.07
Diabetic neuropathy	151 (97.4)	35 (94.6)	186 (96.9)	0.37
San Elian score, mean $\pm$ SD	18.6 $\pm$ 3.0	18.4 $\pm$ 3.4	18.5 $\pm$ 3.0	0.68
San Elian score $\geq$ 20	58 (37.4)	12 (32.4)	70 (36.5)	0.57
Comorbidities				
Previous major amputation	12 (7.7)	2 (5.4)	14 (7.3)	0.87
Previous minor amputation	55 (35.7)	11 (29.7)	66 (34.6)	0.49
Previous diabetic foot hospitalization	32 (20.7)	4 (10.8)	36 (18.8)	0.17
Previous antibiotic therapy	52 (33.6)	16 (43.2)	68 (35.4)	0.27

Previous diabetic foot infection	53 (34.2)	9 (24.3)	62 (32.3)	0.25
GFR, mean $\pm$ SD	87.2 $\pm$ 32.0	95.1 $\pm$ 29.8	88.7 $\pm$ 32	0.18
Laboratory Findings				
Hemoglobin (g/dL), mean $\pm$ SD	10.6 $\pm$ 2.0	11.0 $\pm$ 1.8	10.7 $\pm$ 1.9	0.11
Leukocytes (cells $\times 10^3/\text{mm}^3$), Med (IQR)	11.9 (8.4 to 16.6)	11.5 (8.4 to 16.9)	11.9 (8.4 to 16.6)	0.98
Albumin (g/dL), mean $\pm$ SD	3.0 $\pm$ 0.6	3.2 $\pm$ 0.6	3.0 $\pm$ 0.6	0.14
HbA1c (%), mean $\pm$ SD	9.7 $\pm$ 2.9	11.7 $\pm$ 2.9	10.1 $\pm$ 3.0	0.006
HbA1c $\geq$ 7%	97 (77.6)	31 (93.9)	128 (81.0)	0.03
Microbiological				
Polymicrobial	33 (21.3)	4 (10.8)	37 (19.3)	0.14
Time				
Until last consultation (days)	172 [54 to 448]	137 [89 to 397]	163 [56.5 to 439]	
Internment	23.5 [15 to 32]	17.5 [12 to 31]	22 [15 to 32]	

192 Data are presented as n (%). DM: Diabetes Mellitus. SD: Standard Deviation. Med: Median.

193 IQR: Interquartile Range. GFR: Glomerular Filtration Rate by CKD-EPI. IDSA: Infectious

194 Disease Society American.

195

196 Of a total of 236 isolated bacteria, 82% were MDR. The most common MDR bacteria were

197 *Enterobacteriaceae* (51.3%), *Staphylococcus aureus* (28.4%), and *Enterococcus sp.* (8.9%).

198 Gram-negative bacteria represented 61% of the cases, and only 37 (19.3%) had a

199 polymicrobial culture. A detailed description of the isolated MDR organisms is presented in

200 **Table 2.**

201

202 **Table 2. Microbiological profile of the isolated bacterium according to MDRB.**

203

Total	MDRB (+)	MDRB (-)	p-value
n (%)	n (%)	n (%)	

General	236 (100)	194 (82)	42 (18)	
gram				
Gram-negative	143 (61)	121 (62)	22 (52)	0.23
Gram-positive	93 (39)	73 (38)	20 (48)	
Bacterium				
<i>Enterobacteriaceae</i>	121 (51.3)	102 (52.6)	19 (45.2)	0.01
<i>Pseudomonas sp.</i>	12 (5.1)	10 (5.2)	2 (4.8)	
<i>Acinetobacter sp.</i>	10 (4.2)	9 (4.6)	1 (2.4)	
<i>Staphylococcus sp.</i>	67 (28.4)	56 (28.9)	11 (26.2)	
<i>Enterococcus sp.</i>	21 (8.9)	16 (8.3)	5 (11.9)	
<i>Streptococcus sp.</i>	5 (2.1)	1 (0.5)	4 (9.5)	

204

205

206 The primary outcome (death and/or major amputation) occurred in 18.9% of all patients. The
 207 mortality rate was 2.1%, and major amputation was observed in 17.7%. Regarding secondary
 208 outcomes, 67% of the general population required hospitalization. Of those hospitalized, 80%
 209 had a stay longer than 14 days (**Table 3 and S1 Fig**).

210

211 **Table 3.** Clinical outcomes according to the MDRB pre-secretion.

212

	Total	MDRB (+)	MDRB (-)	p-value
		n (%)	n (%)	
Composite primary outcome	38 /192 (18.9)	36/155 (23.2)	2/37 (5.4)	0.01
(n=192)				
Secondary outcomes				
Mortality (n=192)	4/192 (2.1)	3/155 (1.9)	1/37 (2.7)	0.77

Major amputation (n=188)	34/188 (17.7)	33/152 (21.7)	1/36 (2.8)	0.008
Minor amputation ^b (n=154)	82/154 (53.2)	65/119 (54.6)	17/35 (48.6)	0.53
Hospitalization ^b (n=154)	90/154 (67.0)	66/119 (55.5)	24/35 (68.6)	0.17
Long stay ^c (n=90)	66/90 (80.0)	53/68 (80.3)	13/24 (54.2)	0.013

^bDoes not include fatalities or major amputations. ^cOnly in hospitalized.

The demographic characteristics associated with the primary composite outcome were age over 60 years, duration of diabetes over 10 years, ulcer area larger than 10 cm², depth of the lesion according to Wagner classification[20], infection grade according to IDSA[10], presence of peripheral arterial disease, San Elian score ≥ 20 [15], hemoglobin <10 g/dl, albumin <3.5 g/dl, HbA1c $\geq 7\%$, and polymicrobial culture (**Table 4**).

Table 4. Association between primary composite outcome and population characteristics.

Variable	Primary composite outcome ^a (+) n (%)	Primary composite outcome ^a (-) n (%)	<i>p</i> -value
General	38 (19.8)	154 (80.2)	
Demographic			
Male	25 (18)	117 (82)	0.20
Age > 60 years	31 (32)	65 (68)	0.001
DM duration (years) ≥ 10	32 (24)	101 (76)	0.046
Diabetic foot ulcer			
Wagner classification			
1	0 (0)	5 (100)	0.004
2	1 (6)	17 (94)	

3	8 (11)	64 (89)	
4	29 (30)	68 (70)	
IDSA infection grade			
Mild	2 (9)	21 (91)	<0.001
Moderate	17 (14)	105 (86)	
Severe	19 (40)	28 (60)	
Peripheral arterial disease	29 (41)	42 (59)	0.001
Ulcer recurrence	15 (2)	39 (72)	0.08
Area $\geq 10 \text{ cm}^2$	32 (2)	98 (75)	0.01
Diabetic neuropathy	38 (20)	148 (80)	0.21
San Elian score ≥ 20	22 (31)	48 (69)	0.002
Comorbidities			
Previous major amputation	9 (65)	5 (35)	0.000
Previous minor amputation	11 (17)	55 (83)	0.41
Previous diabetic foot hospitalization	10 (28)	26 (72)	0.18
Previous antibiotic therapy	19 (28)	49 (72)	0.03
Previous diabetic foot infection	15 (24)	47 (76)	0.29
Chronic kidney disease $<60 \text{ ml/min}$	7 (23)	24 (77)	0.84
Laboratory Findings			
Hemoglobin $< 10 \text{ g/dl}$	21 (32)	44 (68)	0.006
Albumin (g/dL) $<3.5 \text{ g/dL}$	29 (33)	60 (67)	0.007
HbA1c $\geq 7\%$	20 (16)	108 (85)	0.003
Microbiological			
Polymicrobial	13 (35)	24 (65)	0.009
Multidrug resistant organism			
<i>Staphylococcus sp.</i> ^b	12 (23)	40 (77)	0.15
<i>Enterococcus sp.</i> ^c	5 (31)	11 (69)	0.20
<i>Enterobacteriaceae</i> ^d	22 (24)	69 (76)	0.26
<i>Pseudomonas sp.</i> ^e	2 (20)	8 (80)	0.49
<i>Acinetobacter sp.</i> ^f	2 (25)	6 (75)	0.57

- 223 ^aPrimary outcome: Mortality and/or major amputation. Total of each bacterium
- 224 ^b_n=67 ^c_n=20 ^d_n=108 ^e_n=12 ^f_n=9.

225

226 In the crude model, for patients with MDRB, the incidence of the primary composite
 227 clinical outcome increased by 3.3 times. However, when adjusted for epidemiological
 228 variables, no association was evidenced in any of the three proposed models. Among the
 229 secondary outcomes, only a hospital stay longer than 14 days was associated with MDRB
 230 when adjusted in any of the three proposed models. The outcomes and their adjusted RR
 231 can be observed in **Table 5**.

232 **Table 5.** Association between MDRB and adverse clinical events: crude and adjusted models.

233

	Model	Crude	<i>p</i> -value	Model 1*	Adjusted	<i>p</i> -value	Model 2**	Adjusted	<i>p</i> -value	Model 3***	Adjusted	<i>p</i> -value
	RR	95% CI		RR	95% CI		RR	95% CI		RR	95% CI	
Composite primary outcome^a												
Not MDRB	1.00			1.00			1.00			1.00		
MDRB	4.29	1.08 – 17.1	0.039	3.40	0.86 – 13.4	0.081	3.28	0.99 – 10.8	0.051	3.29	0.77 – 13.9	0.105
Secondary outcomes												
Mortality												
Not MDRB	1.00			1.00								
MDRB	0.71	0.08-6.72	0.770	0.27	0.04-1.96	0.194	0.53	0.05 – 5.91	0.611	0.27	0.05 – 1.66	0.158
Major amputation												
Not MDRB	1.00			1.00			1.00			1.00		
MDRB	7.81	1.1 – 55.5	0.040	6.45	0.91 – 45.4	0.061	5.41	0.88 – 33.2	0.068	6.55	0.89 – 47.9	0.064
Minor amputation^b												

Not MDRB	1.00			1.00			1.00			1.00		
MDRB	1.12	0.76-1.64	0.544	1.15	0.78-1.69	0.474	0.98	0.68-1.40	0.908	1.20	0.81 – 1.77	0.350
Hospitalization^b												
Not MDRB	1.00			1.00			1.00			1.00		
MDRB	0.81	0.61-1.07	0.133	0.84	0.64-1.11	0.222	0.77	0.59 – 1.01	0.059	0.81	0.59 – 1.10	0.182
Prolonged stay^c												
Not MDRB	1.00			1.00			1.00			1.00		
MDRB	1.49	1.06 – 2.10	0.020	1.45	1.05 – 2.02	0.026	1.46	1.06 – 2.02	0.021	1.51	1.06 – 2.14	0.021

234 ^aPrimary composite outcome: Mortality and/or major amputation. ^bDoes not include deaths or major amputation ($n=154$). ^cOnly in hospitalized $n=90$. RR: Relative risk. CI:
235 confidence interval. *Model 1: Adjusted for age and gender. **Model 2: Adjusted for bone compromise, severe infection, and peripheral arterial disease. *** Model 3: Adjusted
236 for diabetes duration and HbA1C.

DISCUSSION

Main Results

In this study, we found no association between MDRB and the primary outcome of death related to diabetic foot and/or major amputation, but we did find an association with a hospital stay longer than 14 days.

Comparison with other studies

Different studies have shown controversial results regarding the influence of MDRB on the clinical course of DFI. Gupta et al.[7] and Richard et al.[21] concluded that MDRB is not associated with the clinical outcome of patients with DFI. In these studies, the lack of association was attributed to early aggressive treatment, antibiotic therapy adjusted to microbiological findings, and the small number of patients with MDRB included. In our study, after multivariate analysis, no association was defined between MDRB and a higher risk of major amputation. However, Matta et al.'s systematic review did find a higher prevalence of amputation in DFI with MDRB. However, these studies only performed univariate analysis and considered that the higher risk of amputation in their population is more attributed to the metabolic status or immunosuppression of the patients[22].

In our study, we observed an MDRB prevalence of 82% [9], a figure that is significantly higher compared to other countries such as France, India, China, and Turkey, where it fluctuated between 13.8 to 72.5%[22]. One notable outlier was Ethiopia, where a staggering 93% prevalence was reported[23]. This high rate of MDRB in our research might be attributable to several factors. We did not exclude patients who had received

prior antibiotic treatment, a practice known to foster the emergence of resistant bacterial strains[21]. In addition, 20% of our patients had a history of hospitalization due to DFI, potentially predisposing them to selective colonization by resistant pathogens[24]. Furthermore, it's essential to bear in mind that the definition of MDRB can vary across different studies, leading to discrepancies in reported prevalence rates based on the specific criteria employed.

The scientific literature suggests a difference in the prevalence of gram-positive or negative germs depending on the economic level. It is described that the prevalence of gram-negative bacteria is higher in developing countries, as in the studies by Gadepalli et al.[1] and Datta et al.[25]. Similarly, in our study, gram-negative bacteria were the most frequent, finding an 85% bone involvement and an 80% moderate-severe infection, which is related to infection by gram-negative or mixed bacteria. Also, the *Enterobacteriaceae* family presented the highest proportion of MDRB (52.6%), followed by the *Staphylococcus sp.* genus (28.9%), unlike the study by McDonald et al. [26], where *Staphylococcus sp.* was the most common MDR bacteria. The similarities of our results with the studies from India mentioned above[1,25], could be related to the similar degree of hygiene, health education, footwear use, and geographical area related to warm climates. It could also be related to the low budget that the health system invests to create programs that make the management and treatment of patients with DFI more efficient.

Prolonged hospitalization was the only adverse clinical event associated with MDRB, a finding similar to previous studies[8,24], which could suggest nosocomial acquisition through cross-transmission via caregivers' hands[27,28]. The search for hospital care in these patients, as well as the extended stay, may be influenced by factors such as the

complexity of the procedures, the longer duration of ulcers requiring prolonged antibiotic treatment, timely follow-up, and slow recovery of patients with MDRB[8]. Furthermore, it is worth highlighting that 50.5% of patients had a Wagner classification of 4 and 88% had a moderate-severe infection according to IDSA guideline, so it was expected that a longer hospitalization would be due to the severity of their clinical condition[29].

Other factors that modify the relationship between the presence of MDRB and adverse outcomes are polymicrobial culture, vascular insufficiency, anemia, and hyperglycemia. Polymicrobial culture has been associated with the severity of DFI. The symbiosis between two bacteria can potentiate the damage when they are individually present[30]. It is also suggested that vascular insufficiency leads to tissue hypoxia and also causes a decrease in antibiotic concentrations at the site[31]. Similarly, anemia is associated with a decrease in the supply of oxygen to damaged tissues, leading to poor wound healing[32]. Regarding the degree of glycemic control, the population was not similarly distributed in both groups, which does not allow an accurate analysis of the relationship of this variable with adverse outcomes. However, most patients with DFI had suboptimal glycemic control (HbA1c greater than 7% in 77.6% of patients with MDRB and 93.9% of non-MDRB patients), with an average HbA1c above 9%. In our study, there is also a high prevalence of anemia, which distorts the interpretation and influence of this variable.

Importance in public health

Our study revealed a high rate of MDRB, much higher than most reports worldwide. This high rate could distort the impact on outcomes. Given this reality, it's critical that all health facilities establish their bacteriological profile and susceptibility for DFI. This would facilitate the early and effective empirical use of antibiotics according to this profile,

avoiding delays due to the use of limited utility antibiotics that could lead to infection progression. Many MDRB patients, due to intravenous treatments, require continued hospitalization, thereby increasing the intensive use of healthcare personnel. Extended stays heighten the risk of nosocomial infections, escalate direct costs, and limit the opportunity for other patients who require admission. The finding of an association with MDRB suggests an extreme need for careful biosecurity measures against cross-contamination and fomites from healthcare personnel and other patients.

Limitations and Strengths

The high number of patients with MDRB could have limited their influence on outcomes in our cross-sectional analysis. We needed more non-MDRB patients to achieve a close-to-1 exposed/non-exposed ratio and improve estimation precision. Another limitation is the lack of cultures for anaerobic bacteria, which could have altered the distribution of germs in each group (MDRB and non-MDRB) when assessing the association. Additionally, our study's findings cannot be generalized to other populations due to the presence of a Diabetic Foot program, which includes a multidisciplinary team that standardizes treatment, performing surgical debridement within the first 48 hours, contributing to the low rate of adverse DFI clinical outcomes observed.

Key strengths include our use of antibiotic therapy as per the IDSA guidelines and the procedures of the International Working Group of Diabetic Foot for managing peripheral arterial disease, offloading, glycemic management, and nutrition. Also noteworthy are our adherence to recommended standards for sample collection to avoid contamination and the use of a modern system for evaluating bacterial susceptibility.

Conclusion

Our study did not find association between MDRB and death and/or major amputation, but it did with hospitalization exceeding 14 days. The high proportion of MDRB in the total sample and the cross-sectional design may have limited the discovery of differences in the main outcome. Further prospective studies, with larger sample sizes and equivalent studies, are needed to confirm its effect on these outcomes. The high prevalence of MDRB highlights the need for strategies to improve the timely identification of diabetic foot ulcers, as well as proper sample collection to identify pathogens and determine their susceptibility pattern to antibiotics before treatment initiation.

References

1. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. *Diabetes Care*. 2006;29: 1727–1732. doi:10.2337/dc06-0116
2. Bansal E, Garg A, Bhatia S, Attri AK, Chander J. Spectrum of microbial flora in diabetic foot ulcers. *Indian J Pathol Microbiol*. 2008;51: 204–208. doi:10.4103/0377-4929.41685
3. Saravia-Hernández E, Salvador-Carrillo J, Zevallos KAV, Calderón-Ticona J. The landscape of diabetic foot in Peru.: *Investigación Clínica*. 2021;62: 276–289. doi:10.22209/IC.v62n3a07
4. Ozer B, Kalaci A, Semerci E, Duran N, Davul S, Yanat AN. Infections and aerobic bacterial pathogens in diabetic foot. 2010 [cited 27 May 2020]. Available: /paper/Infections-and-aerobic-bacterial-pathogens-in-foot-Ozer-Kalaci/415b949cf52d78bfb8b91e9b2bd18728c14958a7

5. Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? *Clin Microbiol Infect.* 2007;13: 351–353. doi:10.1111/j.1469-0691.2007.01697.x
6. Kathirvel M, Prabakaran V, Jayarajan J, Sivakumar A, Govindan V. Risk factors for the diabetic foot infection with multidrug-resistant microorganisms in South India. *International Surgery Journal.* 2018;5: 675–682. doi:10.18203/2349-2902.isj20180374
7. Gupta S, Attri A, Khanna S, Chander J, Mayankjayant. Outcome in Patients of Diabetic Foot Infection with Multidrug Resistant Organisms. *Journal of Foot and Ankle Surgery (Asia Pacific).* 2018;5: 51–55. doi:10.5005/jp-journals-10040-1089
8. Hartemann-Heurtier A, Robert J, Jacqueminet S, Ha Van G, Golmard JL, Jarlier V, et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. *Diabetic Medicine.* 2004;21: 710–715. doi:10.1111/j.1464-5491.2004.01237.x
9. Richard J-L, Sotto A, Jourdan N, Combescure C, Vannereau D, Rodier M, et al. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. */data/revues/12623636/00340004/08001432/.* 2008 [cited 23 Apr 2020]. Available: <https://www.em-consulte.com/en/article/183575>
10. Lipsky BA, Aragón-Sánchez J, Diggle M, Embil J, Kono S, Lavery L, et al. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. *Diabetes Metab Res Rev.* 2016;32 Suppl 1: 45–74. doi:10.1002/dmrr.2699
11. Crouzet J, Lavigne JP, Richard JL, Sotto A, Nîmes University Hospital Working Group on the Diabetic Foot (GP30). Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. *Int J Infect Dis.* 2011;15: e601-610. doi:10.1016/j.ijid.2011.05.003

12. Department of Surgery, Government Medical College, Kozhikode, Kerala, India, Valappil RK. Multidrug Resistant Organisms in Diabetic Foot Ulcers-Analysis of Risk Factors and Clinical Outcome. *jmscr*. 2017;05: 18138–18183. doi:10.18535/jmscr/v5i2.144. <https://doi.org/10.20453/rmh.v26i3.2584>
13. Jasso-Huamán LE, Villena-Pacheco A, Guevara-Linares X. Control metabólico en pacientes diabéticos ambulatorios de un hospital general. 2015;26: 167-172.
14. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18: 268–281. doi:10.1111/j.1469-0691.2011.03570.x
15. Jesus FRM-D, Ibrahim A, Rodriguez-Ramirez N, Zambrano-Loaiza E. The latin american Saint Elia wound score system (sewss) for the triage of the diabetic foot attack. *Cir Cir*. 2021;89: 679–685. doi:10.24875/CIRU.20000283
16. Clinical Version: eGFR using CKD-EPI (2021 update) | QxMD. In: Calculate by QxMD [Internet]. [cited 17 Jul 2023]. Available: https://qxmd.com/calculate/calculator_251/egfr-using-ckd-epi-2021-update
17. Issue Information. *Diabetes/Metabolism Research and Reviews*. 2020;36: e3293. doi:10.1002/dmrr.3293
18. Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)a. *Clin Infect Dis*. 2013;57: e22–e121. doi:10.1093/cid/cit278
19. VITEK® MS Prime. In: bioMérieux Argentina [Internet]. [cited 17 Jul 2023]. Available: <https://www.bmxclinicaldiagnostics-arg.com/vitek-ms-prime-arg>

- 409 20. Shah P, Inturi R, Anne D, Jadhav D, Viswambharan V, Khadilkar R, et al. Wagner's
410 Classification as a Tool for Treating Diabetic Foot Ulcers: Our Observations at a
411 Suburban Teaching Hospital. *Cureus*. 14: e21501. doi:10.7759/cureus.21501
- 412 21. Richard J-L, Sotto A, Jourdan N, Combescure C, Vannereau D, Rodier M, et al. Risk
413 factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers.
414 *Diabetes Metab*. 2008;34: 363–369. doi:10.1016/j.diabet.2008.02.005
- 415 22. Matta-Gutiérrez G, García-Morales E, García-Álvarez Y, Álvaro-Afonso FJ, Molines-
416 Barroso RJ, Lázaro-Martínez JL. The Influence of Multidrug-Resistant Bacteria on
417 Clinical Outcomes of Diabetic Foot Ulcers: A Systematic Review. *J Clin Med*.
418 2021;10: 1948. doi:10.3390/jcm10091948
- 419 23. Atlaw A, Kebede HB, Abdela AA, Woldeamanuel Y. Bacterial isolates from diabetic
420 foot ulcers and their antimicrobial resistance profile from selected hospitals in Addis
421 Ababa, Ethiopia. *Frontiers in Endocrinology*. 2022;13. Available:
422 <https://www.frontiersin.org/articles/10.3389/fendo.2022.987487>
- 423 24. Zubair M, Malik A, Ahmad J. Clinico-bacteriology and risk factors for the diabetic
424 foot infection with multidrug resistant microorganisms in north India. *Biology and*
425 *Medicine*. 2010;2: 0–0.
- 426 25. Datta P, Chander J, Gupta V, Mohi GK, Attri AK. Evaluation of various risk factors
427 associated with multidrug-resistant organisms isolated from diabetic foot ulcer
428 patients. *J Lab Physicians*. 2019;11: 58–62. doi:10.4103/JLP.JLP_106_18
- 429 26. Macdonald KE, Boeckh S, Stacey HJ, Jones JD. The microbiology of diabetic foot
430 infections: a meta-analysis. *BMC Infect Dis*. 2021;21: 770. doi:10.1186/s12879-021-
431 06516-7
- 432 27. Murali TS, Kavitha S, Spoorthi J, Bhat DV, Prasad ASB, Upton Z, et al.
433 Characteristics of microbial drug resistance and its correlates in chronic diabetic foot

434 ulcer infections. J Med Microbiol. 2014;63: 1377–1385. doi:10.1099/jmm.0.076034-
 435 0

436 28.Islam S, Cawich SO, Budhooram S, Harnarayan P, Mahabir V, Ramsewak S, et al.
 437 Microbial profile of diabetic foot infections in Trinidad and Tobago. Prim Care
 438 Diabetes. 2013;7: 303–308. doi:10.1016/j.pcd.2013.05.001

439 29.Choi SK, Kim CK, Jo DI, Lee MC, Kim JN, Choi HG, et al. Factors Associated with
 440 a Prolonged Length of Hospital Stay in Patients with Diabetic Foot: A Single-Center
 441 Retrospective Study. Arch Plast Surg. 2017;44: 539–544. doi:10.5999/aps.2017.01207

442 30.Hitam SAS, Hassan SA, Maning N. The Significant Association between
 443 Polymicrobial Diabetic Foot Infection and Its Severity and Outcomes. Malays J Med
 444 Sci. 2019;26: 107–114. doi:10.21315/mjms2019.26.1.10

445 31.Aysert Yıldız P, Özdil T, Dizbay M, Güzel Tunçcan Ö, Hızıl K. Peripheral arterial
 446 disease increases the risk of multidrug-resistant bacteria and amputation in diabetic
 447 foot infections. Turk J Med Sci. 2018;48: 845–850. doi:10.3906/sag-1803-217

448 32.Salman I, AL-Shammaree S, Abualkasem B. Low Hemoglobin Levels in Infected
 449 Diabetic Foot Ulcer. IOSR Journal of Pharmacy and Biological Sciences. 2017;12:
 450 05–09. doi:10.9790/3008-1201040509
 451

Supporting information

S1 Fig. Diagram of distribution of outcomes in the study's patients.

S1 Table. Categories and agents used to define *Staphylococcus aureus* MDR, XDR, and PDR.

S2 Table. Categories and agents used to define *Enterococcus sp* MDR, XDR and PDR.

S3 Table. Categories and agents used to define *Enterobacteriaceae* MDR, XDR and PDR.

S4 Table. Categories and agents used to define *Pseudomonas aeruginosa* MDR, XDR and PDR.

S5 Table. Categories and agents used to define *Acinetobacter spp* MDR, XDR and PDR.

S6 Table. Scales used in the study to assess the characteristics of the DFI.

S7 Table. Data collection instrument.




Figure 1